<DOC>
	<DOCNO>NCT02528955</DOCNO>
	<brief_summary>In patient squamous cell carcinoma oral cavity , oropharynx larynx &gt; = pT3 pN+ postoperative radio - radiochemotherapy standard care . Postoperative radiochemotherapy indicate patient multiple lymph node metastasis , lymph node metastasis extracapsular spread R1/2 resection . Locoregional control rate 80 % surgery radio ( chemo ) therapy . But many patient suffer therapy-related long-term side-effects , like xerostomia , dysphagia , fibrosis , trismus etc . The aim study investigate depend primary tumor stage , quality resection ( resection margin ) number lymph node metastasis perform neck dissection adapt de-intensified dose- target volume concept may perform without reduce locoregional-control reduce radiotherapy-related side-effects .</brief_summary>
	<brief_title>De-Intensification Radiotherapy Postoperative Head Neck</brief_title>
	<detailed_description>The study non-randomized phase-II trial . In total 3 therapy arm . Patients assign one therapy arm accord tumor status quality kind surgery . The aim study investigate risk-adapted dose- target-volume concept clearly define patient group possible individualize postoperative radiotherapy without reduce locoregional-control reduce radiotherapy-related side-effects . There two main issue investigate : 1 . Dose prescription primary tumor region : In study investigate dose reduction 56 Gy primary tumor region possible , resection margin &gt; = 5mm , tumor stage &lt; =pT2 risk factor like perineural spread peritumoral lymphangiosis . 2 . Target volume definition elective lymph node level It investigate ipsilateral cervical lymph irradiation alone allow adequate locoregional control select patient : ipsilateral lymph node metastasis &lt; =3 contralateral pN0 ( adequate contralateral selective neck dissection perform ) contralateral cN0 ( patient strictly ipsilateral localize tumor oral cavity oropharynx ) Considering facts 3 therapy group possible : A : Criteria : - pT2 , R ≥ 5 mm , L0 , Pn0 - 3 lymph node metastasis patient &lt; 3 ipsilateral lymph node metastasis bilateral primary tumor without adequate contralateral neck dissection Intervention : - Reduction radiation dose primary tumor region 56 Gy , - Elective Radiotherapy neck side B : Criteria : • &gt; pT2 and/or R &lt; 5mm and/or L1 and/or Pn1 •≤ 3 ipsilateral lymph node metastasis ( contralateral pN0 ( &gt; = 6 resect lymph node ) contralateral cN0 patient wih strictly ipsilateral localise ( &gt; = 5 mm distance midline ) cancer oral cavity oropharynx Intervention •No dose reduction primary tumor region ( prescribe dose primary tumor region : 64 Gy ) •Reduction target volume : elective radiotherapy ipsilateral neck , contralateral neck irradiation C : Criteria - pT2 , R ≥ 5 mm , L0 , Pn0 - 3 ipsilateral lymph node metastasis ( contralateral pN0 ( &gt; = 6 resect lymph node ) contralateral cN0 patient wih strictly ipsilateral localise ( &gt; = 5 mm distance midline ) cancer oral cavity oropharynx Intervention •Reduction radiation dose primary tumor region 56 Gy , AND •Reduction target volume : elective radiotherapy ipsilateral neck , contralateral neck irradiation In arm dose prescription lymph node region follow : •elective lymph node level ( either ipsi- bilateral ) : 50 Gy •lymph node level lymph node metastasis without extracapsular extension : 56Gy - lymph node level lymph node metastasis extracapsular extension : 64 Gy In arm simultaneously chemotherapy recommend following case : - lymph node metastasis extracapsular extension • &gt; = 3 lymph node metastasis All patient stratify accord HPV status . Additional investigation : - swallow endoscopy ( , 6 24 month radiotherapy ) - translational research ( especially individual radiosensitivity , immunologic parameter peripheral blood treatment ) - QoL</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>1 . Histologic proven squamous cell carcinoma oral cavity/larynx/oro hypopharynx 2 . Postoperative tumor status : Oral cavity , oropharynx larynx : pT13 , pN0pN2b Hypopharynx : pT12 ; pN1 3 . Patients fulfill one follow criterion : ≤ pT2 , R ≥ 5 mm , L0 , Pn0 ≤ 3 ipsilateral lymph node metastasis ( contralateral adequate neck dissection perform , contralateral neck dissection recommend patient strictly ipsilateral localise tumor oropharynx oral cavity ) 4 . R0Resection ( resection margin ≥ 1mm ) 5 . No distant metastasis cM0 6. age ≥ 18 year , upper age limit 7 . ECOG ≤ 2 8 . Patients understood protocol content able behave accord protocol 9 . Signed studyspecific consent form prior therapy 10 . In case indicate simultaneous chemotherapy : adequate bone marrow function ( leucocytes &gt; 3,5x10^3 , platelet &gt; 100x 10^3 , hemoglobin &gt; 10g/dl sufficient liver function : bilirubin &lt; 2,0mg/dl , ALT , AST &lt; less 3 time upper limit normal sufficient renal function : normal serum creatinine , glomerular filtration rate &gt; 60ml/min 1. pregnant lactating/nursing woman 2. fertile patient willing use highly effective method contraception ( per institutional standard ) treatment 3 . Any condition potentially hamper compliance study protocol followup schedule 4 . Ontreatment participation trial 5 . R1 R2 resection status 6. pN2c pN3 7. cM1 8. prior radiotherapy head neck region , prior chemo immunotherapy ( neoadjuvant/induction ) 9. time surgery begin radio ( chemo ) therapy &gt; 6 week 10 . Prior ( &gt; 4 month begin radio ( chemo ) therapy ) neck dissection 11 . In case indicate simultaneous chemotherapy : reduce hearing ability ( especially upper frequency range ) know dihydropyrimidindehydrogenase ( DPD ) deficiency simultaneous therapy brivudin DPDinhibitors uncontrolled serious disease , include physical mental disease , example within last 6 month : instable angina pectoris , heart attack , serious cardiac dysrhythmias , stroke , serious carotid stenosis , neurologic psychiatric disorder include epilepsy , dementia , psychosis ; uncontrolled infection ; liver cirrhosis Child B C , severe hepatic impairment ; severe blood count change ; severe renal impairment , HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Head neck cancer</keyword>
	<keyword>postoperative</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>de-intensification</keyword>
</DOC>